September 18 2017 - Sanofi and Amgen tout benefits for PCSK9 inhibitors for diabetic patients

Sanofi and Amgen tout benefits of PCSK9 inhibitors for diabetic patients, the top cancer immunotherapies expected to reach $1 billion in sales this year, the biotech rally isn’t over yet, and more - scroll down for the latest news

For banking news and anonymous forums, be sure to check out cafebanking.com